Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — Investor Presentation (May 2022)
76 slides from Tonix Pharmaceuticals's investor presentation, May 9, 2022
Slide 1: Investor Presentation
PHARMACEUTICALS INVESTOR PRESENTATION NASDAQ: TNXP Version P0351 May 9, 2022 (Doc 1009)
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be i
Slide 3: What we do
What we do OUR MISSION ADVANCING THE SCIENCE AND UNDERSTANDING OF DISEASES 7 a by developing innovative therapies that improve population health ? ad by focusing on unmet needs in patient care y OUR STRATEGY Using our integrated development engine, we advance innovative programs across multiple ther
Slide 4: Pipeline: Central Nervous System (CNS) Portfolio
Pipeline: Central Nervous System (CNS) Portfolio CANDIDATES* INDICATION Fibromyalgia (FM) TNX-102 SL" Posttraumatic Stress Disorder (PTSD) Long COVID (PASC?) Cocaine Intoxication / Overdose 13004 TNX-1300 FDA Breakthrough Designation TNX-19005 Migraine, Craniofacial Pain and Binge Eating Disorder TN
Slide 5: Pipeline: Immunology and Immuno-Oncology portfolio
Pipeline Immunology and Immuno-Oncology portfolio = = Se gly - US / NEXT z NDIDATES* INDICATION fe 23 FS) MILESTONE 5 No TNX-1500! Organ Transplant Rejection/ Autoimmune Conditions | Phase 1, Targeted 2H 2022 Start © TNX-17002 Gastric and colorectal cancers Preclinical a 5 w 3 a > =| fe) = {eo} o »
Slide 6: Pipeline: Infectious Disease Portfolio
Pipeline Infectious Disease Portfolio : ATUS / NEXT & CANDIDATES INDICATION MILEST ONE TNX-8011 Smallpox and monkeypox vaccine TNX-1840/TNX-18502_ COVID-19 Vaccine (horsepox-based live virus vaccine) TINX-2300% COVID-19 Vaccine Preclinical TNX-35004 COVID-19 Antiviral Preclinical _£ TNX-36005 COVID-
Slide 7: Pipeline: Rare Disease Portfolio
Pipeline Rare Disease Portfolio NDI * STATUS / NEXT ES INDICATION MILESTONE Prader-Willi Syndrome a HNx=22007 FDA Orphan Drug Designation Erecinical - OM04LNOd ASVASIGC 3YVva “All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.
Slide 8: CNS: Key Candidates
CNS: KEY CANDIDATES és
Slide 9: TNX-102 SL: Fibromyalgia
TNX-102 SL*: Fibromyalgia Cyclobenzaprine Protectic® Sublingual tablets PROFILE DEVELOPMENT PROGRAM A unique formulation of cyclobenzaprine Market Entry: Fibromyalgia designed to optimize delivery and absorption Q Zz oO vu ie) a oq mul fo) [= {e) : ‘ . Additional Indications: Long COVID, Innovative
Slide 10: TNX-102 SL: Fibromyalgia Program Update
TNX-102 SL: Fibromyalgia Program Update Ld Phase 3 Study, RESILIENT (F307), will compare TNX-102 SL 5.6 mg and placebo ¢ First patient enrolled in April 2022 ¢ Interim Analysis results expected 1Q 2023 O1104L4Od SND ¢ Parallel design, double-blind, randomized placebo-controlled study, all U.S. sites
Slide 11: Role of Infections in Triggering Fibromyalgia or CFS-Like Illnesses
Role of Infections in Triggering Fibromyalgia or Chronic fatigue (CFS)-Like Illnesses (2) Zz o vu fe} a = nn ie} rE Infection initiates an autoreactive process, which affects several functions, including brain and energy metabolism'* Infections can trigger any of these conditions in approximately 10
Slide 12: TNX-102 SL: Long COVID
TNX-102 SL: Long COVID a.k.a Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) » Long COVID is a heterogeneous condition that displays elements of nociplastic pain in many individuals, who experience otherwise unexplained'2: /1O4LYOd SND. + Symptoms (multi-site pain, fatigue, sleep disorders and co
Slide 13: New Classification for Central Pain: Nociplastic Pain
New Classification for Central Pain: Nociplastic Pain‘ Pain due to the activation of nociceptors that arises from actual or threatened damage to non- : J neural tissue Nociceptive pain Neuropathic pain 1 Pain that arises from altered nociception i Nociplastic } despite no clear evidence of tissue da
Slide 14: Timeline of Long COVID After Acute COVID-19
Timeline of Long COVID After Acute COVID-19 Post-Viral Syndrome’? (2) ~4 77) uv g Acute COVID-19 Long COVID ee 7 Detection unlikely PCR positive PCR negative i) (e) + Anxiety/depression 5 + Muscle weakness + Sleep problems, * Headaches + Brain fog & 62 . perce) Nasopharyngeal + Fati + Coug! Ey ange
Slide 15: Prevalence of Long COVID
Prevalence of Long COVID ~30% of Recovered SARS-CoV-2 Patients after 6 Months fe) Zz (77) uv fe) a 4 mul 9 ~50% of patients ~35% of patients ~30% of patients ry ' ro} experience Long COVID experience Long COVID experience Long COVID symptoms? symptoms? symptoms if A 30 days 60-180 days >180 days Lon
Slide 16: Rate of Central Sensitization in Long COVID survey
Rate of Central Sensitization (CS) in Long COVID survey CS Symptoms reported in 70%! Prevalence of CS in Long COVID patients O1104L4Od SND 70% of Long COVID participants had CS symptoms (CSI?>=40/100) 65% of Long COVID participants had severe CS symptoms 491 total participants Long COVID with CSI 24
Slide 17: Long COVID Patients in TriNetX Study
Long COVID Patients in TriNetX Study’ Retrospective Observational Database Study TriNetX Dataworks USA Network2: + Afederated network of inpatient and outpatient electronic medical records from 48 US. healthcare organizations (HCOs) The platform returns aggregated patient counts and results from HCO
Slide 18: Long COVID Patients in TriNetX Study: Fibromyalgia-like Symptoms
Long COVID Patients in TriNetX study‘ Fibromyalgia-like Symptoms (Multi-Site Pain) in Over 40% of Patients’ is} 177) 52,322 total Long COVID patients 21,694 total FM-like Long COVID patients 3} | ml fe) IE a (e) 1 Mull pe a Multi-site pain only % No multi-site pain } Multi-site pain and fatigue Mult
Slide 19: Long COVID Patients in TriNetX Study: Medication Use
Long COVID Patients in TriNetX Study’ Recorded Medication Use, Days 91-180 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of patients Patients with compounding nociplastic symptoms are medicating with opioids, antidepressants and anxiolytics at higher rates than those with only multi-site pain
Slide 20: Rate of Opioid Use in Long COVID Patients
Rate of Opioid Use in Long COVID Patients Potential Health Concern ~ In only a few days some 100% 01104L4Od SND. people can develop a 4 physical dependence and 90% addiction to opioids? 6 80% aD < 70% > The USA Department of x « ; ‘ 9 x z Labor estimates that 1 in 4 £ 60% Ss oz ; < oa wo 3 & & Legen
Slide 21: Significant Financial Impact of Long COVID
Significant Financial Impact of Long COVID for Households and Economies 25% of Long COVID patients are unable to return to work" ° Zz Oo u oO a S| 7 fe) i fo} lost due to Long COVID in the UK? afin | [ Over 250,000 Quality Adjusted Life-Years (QUALYS) will be = $23.3 billion is estimated to be paid
Slide 22: Long COVID Presidential Memorandum
Long COVID Presidential Memorandum President Biden — April 5, 20221 Policy * Commits to redoubling efforts to address the long-term effects of COVID-19 Organizing Government Wide Response * Harnesses the full potential of the Federal Government, in coordination with public- and private-sector partne
Slide 23: Long COVID and Vaccination
Long COVID and Vaccination Recent Reports’ Vaccination may not change risk of Long COVID after Breakthrough COVID-19 + Aretrospective cohort study of 10,024 breakthrough infection in the US showed no benefit of vaccination in decreasing Long COVID after breakthrough infection’ — Vaccination has bene
Slide 24: TNX-102 SL: Long COVID (PASC)
TNX-102 SL*: Long COVID (PASC) Cyclobenzaprine Protectic® Sublingual Tablets Q Zz oO vu ie) a oq mul fo) [= {e) PROFILE DEVELOPMENT PROGRAM Long COVID or Post-acute Sequelae of COVID-19 Market Entry: Long COVID (PASC) (PASC?) + Symptoms can include fatigue, sleep disorders, pain, fevers, Status: Cli
Slide 25: Opportunities to Expand TNX-102 SL to Other Indications
Opportunities to Expand TNX-102 SL to Other Indications Role of sleep disturbance more established in common psychiatric and neurological/pain disorders + Recognized as a core symptom of many of these disorders 1O4LYOd SND. + Traditional sleep medications, which increase sleep quantity, may not prov
Slide 26: TNX-1300: Cocaine Intoxication
TNX-1300*: Cocaine Intoxication Cocaine Esterase (CocE) PROFILE DEVELOPMENT PROGRAM Cocaine is the main cause for drug-related Market Entry: Cocaine Intoxication ED visits’ . Q Zz oO vu ie) a oq mul fo) [= {e) F P A Additional Indications: Cocaine Overdose Cocaine use can cause irreversible structur
Slide 27: TNX-1900: Migraine
TNX-1900*: Migraine Intranasal Potentiated Oxytocin (OT) with Magnesium Q Zz oO vu ie) a oq mul fo) [= {e) PROFILE DEVELOPMENT PROGRAM Intranasal OT has potential utility in treating Market Entry: Chronic Migraine migraine’ + Intranasal OT reaches the trigeminal ganglion Additional Indications: Acut
Slide 28: TNX-1900 for Migraine: Magnesium at the Core of Oxytocin Binding
TNX-1900* for Migraine Magnesium (Mg?*) is at the Core of Oxytocin Binding’ TNX-1900 contains magnesium: Recent structural studies show magnesium is at the core of oxytocin binding to oxytocin receptor’ Oxytocin Oxytocin receptor ‘Adapted from Meyerowitz, J.G., Robertson, M.J., Barros-Alvarez, X. ef
Slide 29: TNX-601 CR: Depression
TNX-601 CR*: Depression Tianeptine Oxalate and Naloxone Q Zz Oo vu fe) a oq mul fo) [= e) PROFILE DEVELOPMENT PROGRAM Anovel, oral, controlled release once-daily Market Entry: Major Depressive Disorder tablet Mechanistically different from traditional Reena indications: aS ¢ 4 monoaminergic treatmen
Slide 30: Immunology: Key Candidates
TONIX | PHARMACEUT| IMMUNOLOGY: KEY CANDIDATES
Slide 31: TNX-1500: Prophylaxis of Transplant Rejection
TNX-1500 (a-CD40L mAb): Prophylaxis of Transplant Rejection Potential Treatment for Autoimmune Conditions Targeted as a first-line monotherapy for autoimmunity and add-on therapy for preventing and treating organ transplant rejection + Distinct mechanism of action (MOA)—TNX-1500 blocks T cell helper
Slide 32: TNX-1500 (a-CD40 Ligand) Markets
TNX-1500 (a-CD40 Ligand) rity Organ transplant rejection drugs $4.7 billion’ ‘Global market as of 2018 (hitps:/iww. biospace.comfartcle/organ-transplant-rejection-medications-market-drug-companies-focus-on-improving-long-term-outcome-of-new-drugs/) 2Wang, Jettrey H. and Hart, Alyson, Kidney360 Novem
Slide 33: About CD40L (also called CD154)
About CD40L (also called CD154) > CDA4O0L is a transiently expressed T cell surface molecule and is also called CD15414 — Predominantly expressed by T cells and interacts with CD40 on B cells and macrophages > Mediates T cell helper function’ ry — Activates B cells for humoral (antibody-mediated) im
Slide 34: TNX-1500: Prevention of Allograft Rejection
TNX-1500*: Prevention of Allograft Rejection Next Generation a-CD40 Ligand (CD40L) Antibody Second Generation: Eliminated the FcyR TE complication but potency and half life was reduced, limiting utility = - = THE CD40-CD4O0L pathway is a pivotal immune system s modulator and a well-established and p
Slide 35: Third-Generation a-CD40L
Third-Generation a-CD40L Engineered to Decrease Risk of Thrombosis = 7 = Cc z : ‘ r &) First-generation Second-generation Third-generation 5 anti-CD40L mAbs anti-CD40L mAbs anti-CD40L mAbs* 6) vu 2} a o nu fe} = ° Ruplizumab Aglycosyl Dapirolizumab Letolizumab TNX-1500 Ruplizumab Constant fragment (
Slide 36: a-CD40L Treatment to Prevent Allograft Rejection
a-CD40L Treatment to Prevent Allograft Rejection * Calcineurin inhibitors (CNIs), mainly tacrolimus, are the cornerstone of immunosuppressive therapy? ° However, CNis cause irreversible and progressive deterioration of kidney function in all types of solid organ transplants®+ * Costimulation blockad
Slide 37: Non-Human Primate Heart Heterotopic Allograft Study
Non-Human Primate Heart Heterotopic Allograft Study Dr. Richard Pierson, Mass General Hospital > TNX-1500 monotherapy consistently (4/5 heart transplants) prevents heart transplant rejection’ — Graft acceptance without acute cellular injury? or chronic antibody injury* through day 180 — Prolonged ac
Slide 38: Non-Human Primate Kidney Allo-Transplantation Study
Non-Human Primate Kidney Allo-Transplantation Study Dr. Tatsuo Kawai, Mass General Hospital > TNX-1500 monotherapy consistently (5/6 kidney transplants) prevents kidney transplant rejection’ — Six recipients were treated with TNX-1500 monotherapy — No rejection was observed in 5/6 recipients through
Slide 39: Tolerance Induction with Donor Bone Marrow Transplantation
Tolerance Induction with Donor Bone Marrow Transplantation Induction of “mixed chimerism” induces allograft tolerance — Long-lasting, durable tolerance—specifically to donor tissues — Initial protocols required that the recipient’s mature T cells be severely depleted Tolerance induction via “mixed c
Slide 40: Non-Human Primate Combined Kidney and Bone Marrow Transplantation
Non-Human Primate Combined Kidney and Bone marrow Transplantation (CKBMT) with TNX-1500 induced allograft tolerance Dr. Tatsuo Kawai, Mass General Hospital A. CONDITIONING REGIMEN FOR BONE MARROW & KIDNEY TX The nonhuman primate recipient received the conditioning regimen that includes low dose tota
Slide 41: a-CD40L Beyond Allografts: Xenografts
© a-CD40L Beyond Allografts: Xenografts = = s Allotransplantation is limited by a critical Concept for Pig-to-Human Xenotransplantation'2 9 - nia-to- fo} Shortage of human organs; pig-to-human Modifications to the pig genome Longest Pig-to- © xenotransplantation offers a promising greatly reduce ris
Slide 42: Recent Xenotransplant Headlines
Recent Xenotransplant Headlines The New York Eimes “In a First, Surgeons Attached a Pig Kidney toa Human, and It Worked” Roni Caryn Rabin October 19, 2021 THE WALL STREET JOURNAL. “Saved by a Pig’s Heart” The Editorial Board January 12, 2022 THE WALL STREET JOURNAL. “Pig Kidneys Transplanted Into Br
Slide 43: a-CD40L Beyond Transplantation: Autoimmunity
a-CD40L Beyond Transplantation: Autoimmunity ¢ Autoimmune diseases are also characterized by immune system activity that attacks “self,” which can damage various parts of the body"? * First-generation anti-CD40L Abs showed evidence of efficacy in autoimmunity before trials © were halted due to throm
Slide 44: TNX-1500: Key Considerations
TNX-1500: Key Considerations ¢ TNX-1500 may be used in large markets that are not currently well served * There is a long history of use of monoclonal antibodies 4 * Tonix has engineered a safer, potentially more efficacious molecule than previous | anti-CD40L mAbs > ¢ Intellectual property is in pl
Slide 45: Development and Regulatory Strategy
Development and Regulatory Strategy 15t Indication — Kidney allotransplantation (human to human) — Replacement for nephrotoxic CNI’s (calcineurin inhibitors, e.g. Prograf® (tacrolimus)', Neoral® (cyclosporin)? — Similar development path to the successful development of BMS’s Nulojix® (belatacept)?,
Slide 46: TNFa Superfamily Members are Targeted by mAbs
TNFa Superfamily Members are Targeted by mAbs * CD4O0L is a member of the Tumor Necrosis Factor (TNFa) Superfamily’ * Other TNFa Superfamily members have proven to be effective targets for antagonist (blocking) mAbs? anti-TNFa mAbs for the treatment of certain autoimmune conditions + infliximab (Rem
Slide 47: Recent mAb Transactions
“us Recent mAb Transactions = = c 2020 2021 2022 z September October January March 5 (9) < |____| a 3} a t 4 = Immunomedics acquired Momenta acquired by Kymab acquired by Sanofi for $1.1B° Sanofi and IGM Biosciences fo) by Gilead for $21B* Johnson & Johnson for «Is an anti-Ox40L for the treatment of
Slide 48: Monoclonal Antibodies Represent Top Products by 2021 Sales
Monoclonal Antibodies (mAbs) Represent 4 of Top 10 Products by 2021 Sales * Over 100 mAbs have been approved by the US FDA, and significant growth potential remains‘ * Global mAb market is projected to grow from $179B in 2021 to $452B in 2028 at a CAGR of 14.1%? TOP 10 DRUGS BY GLOBAL SALES IN 2021
Slide 49: TNX-1700: Gastric and Colorectal cancers
TNX-1700*: Gastric and Colorectal cancers Stabilized Recombinant Trefoil Factor 2 (rTFF2) Next Steps: Animal studies ongoing PRECLINICAL EVIDENCE FOR INHIBITING GROWHT OF CANCER CELLS + Data showed that TFF2-CTP augmented the efficacy of mAb anti-PD-1 therapy. Anti-PD-1 in combination with TFF2-CTP
Slide 50: Infectious Disease: Key Candidates
TONIX PHARMACEUTICALS INFECTIOUS DISEASE: KEY CANDIDATES
Slide 51: TNX-801: Smallpox and Monkeypox Vaccine
) TNX-801: Smallpox and Monkeypox Vaccine Live Virus Platform Development Program APPLICATION OF LIVE VIRUS PLATFORM DEVELOPMENT PROGRAM + TNX-801 is a cloned version of horsepox' (without any insert) purified from cell culture Market Entry: Smallpox and + In addition to being a potential addition t
Slide 52: Live Virus Vaccines: Development Rationale
Live Virus Vaccines: Development Rationale Control of smallpox, measles, mumps, rubella, chickenpox and other viral conditions — Prevent forward transmission Effective in eliciting durable or long-term immunity A Economical to manufacture at scale — Low dose because replication amplifies dose in viv
Slide 53: Vaccinia and Horsepox Induce a Skin Reaction Called a Take
) Vaccinia and Horsepox Induce a Skin Reaction Called a “Take” Described by Dr. Edward Jenner ¢ Biomarker of protection — Smallpox was eradicated using this marker — Revaccination indicated for recipients without “take” Vaccine * Measure of T cell immunity — No need for blood draws or complex labora
Slide 54: Live Virus Recombinant Pox Vaccine (RPV) Platform Profile
) Live Virus Recombinant Pox Vaccine (RPV) Platform Profile POTENTIALLY LONGER DURABILITY DUE TO POX-ENGINEERED ARCHITECTURE * Live virus vaccines present unique “danger signals” resulting in strong immune response | PROGRAMMABLE VECTOR DESIGN FOR USE IN DIFFERENT DISEASE MODELS’ + Large capacity fo
Slide 55: Live Virus Vaccine Platform: Recombinant Pox Vaccine (RPV)
Live Virus Vaccine Platform: Recombinant Pox Vaccine (RPV) Technology for Emerging Infectious Diseases and Oncolytics COVID-19 Biodefense ¥ Vaccinia Horsepox Future Pandemics: Infectious Disease _— Oncology RPV VECTOR BELIEVED SIMILAR TO EDWARD JENNER’S VACCINE** O011041L4Od ASVASIG SNOILDSSNI Using
Slide 56: COVID-19: Entering Endemic Phase in the US
COVID-19: Entering Endemic Phase in the US * Delta and Omicron variant waves are waning in most parts of the US — Leaving a path of morbidity and mortality, including “breakthrough” infection and disease among vaccinated and convalescent * U.S. states are rolling back state pandemic restrictions -—
Slide 57: COVID-19: The Missing Pieces
COVID-19: The Missing Pieces * Vaccines: early vaccines slowed pandemic, but are showing limitations — Short term protection — requirement for boosters with mRNA vaccines; — Increasing focus on preventing hospitalization and death + Anti-viral drugs: Veklury® (remdesivir), Paxlovid™ (nirmatrelvir'),
Slide 58: COVID-19 Vaccines: Where We Are Today
COVID-19 Vaccines: Where We Are Today Durability of protection — mRNA vaccinated people lose protection, starting at 4-6 months" — High rates of “breakthrough” COVID during Delta and Omicron waves — Booster vaccinations with mRNA vaccines recommended at 4-6 months Effect on forward transmission (spr
Slide 59: COVID-19 Vaccines: Where Do We Go From Here?
COVID-19 Vaccines: Where Do We Go From Here? mRNA vaccines have slowed pandemic, but may not be a long-term solution — Vaccinated people lost protection and showed high rates of “breakthrough” COVID during Delta and Omicron waves — COVID is becoming endemic in the US; vaccination of entire world eve
Slide 60: TNX-1840 and TNX-1850: COVID-19 Vaccine
@ TNX-1840 and TNX-1850*: COVID-19 Vaccine Live Virus Platform Development Program APPLICATION OF LIVE VIRUS PLATFORM DEVELOPMENT PROGRAM + First version TNX-1800 encodes spike protein from SARS- CoV-2, Wuhan strain Market Entry: COVID-19 Vaccine + Planned new versions TNX-1840 and TNX-1850 encode s
Slide 61: What Makes TNX-1840 and TNX-1850 Different from mRNA Vaccines
Live Virus Platform: What Makes TNX-1840 and TNX-1850 Different from mRNA Vaccines CRITERIA mRNA VACCINES O/TNX-1850 Number of shots Two One Duration 6 months Years / decades t Boosters Recommended Likely not required Protection from variants Decreased Expected Forward transmission Unknown for varia
Slide 62: TNX-2300: COVID-19 Vaccine
@ TNX-2300*: COVID-19 Vaccine Live Virus Vaccine Based on Bovine Parainfluenza (BPI) Virus LIVE VIRUS VACCINE* DEVELOPMENT PROGRAM + Previously has been shown to be an effective antigen delivery vector in humans, notably well tolerated in infants and Market Entry: COVID-19 Vaccine children + Vector
Slide 63: Internal Development & Manufacturing Capabilities
es) Live Virus RPV Platform & COVID-19 Vaccine Internal Development & Manufacturing Capabilities Infectious Disease R&D Center (RDC) — Frederick, MD + Function: Accelerated development of vaccines and antiviral drugs against COVID-19, its variants and other infectious diseases + Description: ~48,000
Slide 64: American Pandemic Preparedness Plan (AP3)
American Pandemic Preparedness Plan (AP3) ¢ “Platforms” — Foundation of Pandemic Response — Key element of AP3 from White House Office of Science and Technology Policy or OSTP'2 = 100 days to human trials ‘ = Technologies that do not require sterile injection t= 7 | ° TNX-801/-1840/-1850 (live virus
Slide 65: Small Molecule COVID-19 Therapeutics
Small Molecule COVID-19 Therapeutics The only COVID-19 antiviral that is FDA approved is Remdesivir/Veklury® Gilead — Intravenous (i.v.) medicine FDA approved for patients who are at least 12 years old and require hospitalization May shorten the time to recover from acute COVID-19 World Health Organ
Slide 66: TNX-3500: COVID-19 Antiviral Treatment
TNX-3500*: COVID-19 Antiviral Treatment @ Sangivamycin PROFILE DEVELOPMENT PROGRAM New variants heighten need for therapeutics Market Entry: COVID-19 Antiviral NIH Treatment Guidelines for COVID-19 are mixed on use of remdesivir Additional Indications: MERS, Ebola, Lassa, ¥ Oncology Potential monoth
Slide 67: Monoclonal Antibody COVID-19 Therapeutics
Monoclonal Antibody COVID-19 Therapeutics Monoclonal antibodies (mAbs) (EUA) — 3 with US Emergency Use Authorization’ — Vir/GSK —- XEVURDY® (sotrovimab)' — ONLY mAb that was active against omicron, but now withdrawn from distribution in 8 states because of insufficient activity against BA.22 — Lilly
Slide 68: TNX-3600: COVID-19 Therapeutics
@ TNX-3600*: COVID-19 Therapeutics Fully Human Monoclonal Antibody Platform PROFILE DEVELOPMENT PROGRAM Collaboration with Columbia University Market Entry: COVID-19 Therapeutic Human monoclonal antibodies (mAbs) generated from COVID-19 convalescent patients Additional Indications: Symptomatic COVID
Slide 69: TNX-3700: COVID-19 Vaccine
@ TNX-3700*: COVID-19 Vaccine Zinc Nanoparticle (ZNP) Formulation for mRNA Vaccines PROFILE DEVELOPMENT PROGRAM Collaboration with Kansas State University Market Entry: Booster for COVID- 19 Vaccines ZNP technology is a potential replacement for the Lipid Nanoparticle (LNP) technology of current mRN
Slide 70: Rare Disease: Key Candidates
TONIX | PHARMACEUT! RARE DISEASE: KEY CANDIDATES —
Slide 71: TNX-2900: Prader-Willi Syndrome
TNX-2900*: Prader-Willi Syndrome Intranasal Potentiated Oxytocin (OT) with Magnesium 2 = a PROFILE DEVELOPMENT PROGRAM a Prader-Willi Syndrome is the most common Market Entry: Prader-Willi Syndrome m genetic cause of life-threatening childhood in obesity Additional Indications: Rare ry 4 + Rare dise
Slide 72: Future Outlook
FUTURE OUTLOOK ; :
Slide 73: Partners
tners MASSACHUSETTS GENERAL HOSPITAL MEDIGAWECHOGL TNX-1500: ALLOGRAFT REJECTION ® ge) UNIVERSITE STANFORD “DE GENEVE anvensir UNIVERSITY OF ALBERTA RESEARCH TNX-1900: MIGRAINE & OTHER INDICATIONS SMALLPOX AND MONKEYPOX VACCINE TNX-1840 and TNX-1850: COVID-19 VACCINES TNX-1300: COCAINE INTOXICATION
Slide 74: Milestones: Recently Completed and Upcoming
Milestones: Recently Completed and Upcoming* whe Quarter 2021 Non-human primate positive efficacy data from TNX-1800 in COVID-19 models reported wis Quarter 2022 Topline data from Phase 3 F306/RALLY study of TNX-102 SL for the management of fibromyalgia of ona Quarter 2022 Phase 3 F307/RESILIENT stu
Slide 75: Management Team
Management Team Xela... Seth Lederman, MD TARGENT~ = Fusilev Co-Founder, CEO & Chairman eee ee Gregory Sullivan, MD Couustaia Untvenstry New York State ¥ | Chief Medical Officer <== Department of Psychiatry Psychiatric Institute Bradley Saenger, CPA . A - Chief Financial Officer Shire VERTEX 2 pwe J
Slide 76: Thank You
THANK YOU
Tonix Pharmaceuticals Holding — Investor Presentation (May 2022) on 6ix